These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31686001)

  • 41. A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
    Böhnke N; Berger M; Griebenow N; Rottmann A; Erkelenz M; Hammer S; Berndt S; Günther J; Wengner AM; Stelte-Ludwig B; Mahlert C; Greven S; Dietz L; Jörißen H; Barak N; Bömer U; Hillig RC; Eberspaecher U; Weiske J; Giese A; Mumberg D; Nising CF; Weinmann H; Sommer A
    Bioconjug Chem; 2022 Jun; 33(6):1210-1221. PubMed ID: 35658441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery.
    Richards DA
    Drug Discov Today Technol; 2018 Dec; 30():35-46. PubMed ID: 30553519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
    Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y
    J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
    Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
    Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
    Neumann CS; Olivas KC; Anderson ME; Cochran JH; Jin S; Li F; Loftus LV; Meyer DW; Neale J; Nix JC; Pittman PG; Simmons JK; Ulrich ML; Waight AB; Wong A; Zaval MC; Zeng W; Lyon RP; Senter PD
    Mol Cancer Ther; 2018 Dec; 17(12):2633-2642. PubMed ID: 30242091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
    Ross PL; Wolfe JL
    J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
    Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ
    Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
    Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
    Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
    Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates.
    Walker JA; Sorkin MR; Ledesma F; Kabaria SR; Barfield RM; Rabuka D; Alabi CA
    Bioconjug Chem; 2019 Nov; 30(11):2982-2988. PubMed ID: 31671265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.
    Zimmerman ES; Heibeck TH; Gill A; Li X; Murray CJ; Madlansacay MR; Tran C; Uter NT; Yin G; Rivers PJ; Yam AY; Wang WD; Steiner AR; Bajad SU; Penta K; Yang W; Hallam TJ; Thanos CD; Sato AK
    Bioconjug Chem; 2014 Feb; 25(2):351-61. PubMed ID: 24437342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates.
    Albers AE; Garofalo AW; Drake PM; Kudirka R; de Hart GW; Barfield RM; Baker J; Banas S; Rabuka D
    Eur J Med Chem; 2014 Dec; 88():3-9. PubMed ID: 25176286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
    Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
    Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
    J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Site-specific antibody-drug conjugation through glycoengineering.
    Zhou Q; Stefano JE; Manning C; Kyazike J; Chen B; Gianolio DA; Park A; Busch M; Bird J; Zheng X; Simonds-Mannes H; Kim J; Gregory RC; Miller RJ; Brondyk WH; Dhal PK; Pan CQ
    Bioconjug Chem; 2014 Mar; 25(3):510-20. PubMed ID: 24533768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.